Mathai Mammen (Rob Tannenbaum, Endpoints News at BIO 2018)
August 8, 2022 07:54 PM EDTUpdated August 9, 06:57 AM
People

Math­ai Mam­men makes an abrupt ex­it as head of the big R&D group at J&J

John Carroll

Editor & Founder

In an af­ter-the-bell shock­er, J&J an­nounced Mon­day evening that Math­ai Mam­men has abrupt­ly ex­it­ed J&J as head of its top-10 R&D group.

Re­cruit­ed from Mer­ck …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times